FDA Authorizes Expanded Clinical Trial for Aquedeon’s Duett System

The FDA has given Aquedeon Medical clearance to expand its clinical trial of the Duett vascular graft system to 90 patients. This marks an important step toward advancing surgical methods in thoracic aortic arch reconstruction — one of the most technically demanding procedures in cardiovascular surgery. The Duett system is designed to shorten deep hypothermic circulatory arrest (DHCA) time and restore cerebral perfusion more quickly, offering the potential to reshape aortic surgery practices.

The FDA’s approval represents a key milestone for Aquedeon Medical in addressing the challenges of open thoracic aortic arch surgery, particularly those performed under DHCA. The expanded trial reflects growing confidence in the Duett system’s ability to improve efficiency, precision, and patient outcomes. By simplifying the vascular anastomosis process, the system aims to reduce operative times while maintaining high surgical standards — aligning with a broader industry push toward safer, more efficient cardiovascular procedures.

With FDA authorization to proceed, Aquedeon Medical can further evaluate the Duett system’s potential to significantly improve aortic arch surgery. By prioritizing procedural efficiency and patient safety, this technology could play a pivotal role in shaping the next generation of cardiovascular surgical innovation.

For the latest updates and in-depth insights into the world of Medical Devices, including breakthrough treatments, industry trends, and regulatory news, contact Steffan Mortimer today!